Laura Soucek

Personal Info

Address
Vall d'Hebron Institute of Oncology (VHIO)
CELLEX Centre
C/ Natzaret, 115-117; 3rd. Floor
08035 Barcelona, Spain

Phone
+34.93 254 3450

Mobile
+34.695207869

E-mail
lsoucek@vhio.net

LinkedIn
https://www.linkedin.com/in/laurasoucek/

Twitter
@LauraSoucek

Languages

- Italian: mother tongue
- English: C2
- Spanish: C1
- Catalan: B1

Positions

Director of the Preclinical and Translational Program and Principal Investigator of the Models of Cancer Therapies Laboratory, Vall d'Hebron Institute of Oncology (VHIO).

Research Professor, ICREA (Catalan Institution for Research and Advanced Studies).

Associate Professor at the Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona (UAB).

Founder and CEO of Peptomyc S.L..

Education

1998-2001 University of Rome "La Sapienza"
PhD student in Genetics and Molecular Biology at the Department of Genetics and Molecular Biology. Supervisors: Prof. Gianni Cesareni and Dr. Sergio Nasi.

1996-1998 University of Rome "La Sapienza"
Graduate student at Centro di studi per gli Acidi Nucleici, C.N.R., Department of Genetics and Molecular Biology, Supervisor: Dr. Sergio Nasi.

1991-1996 University of Rome "La Sapienza".
Laurea Cum Laude in Biology, Supervisor: Dr. Sergio Nasi.

1986-1991 Liceo Classico A. Mancinelli, Velletri (RM), Italy.
High school degree in classical studies. Full marks

Previous positions held

2006-2011 Assistant Researcher at UCSF, San Francisco, CA, USA. PI: Prof. Gerard Evan.

2003-2006 Postdoctoral Fellow at Cancer Research Institute, UCSF. PI: Prof. Gerard Evan.

2002-2003 Molecular Biologist at IBPM, CNR, Rome, Italy. Supervisor: Dr. Sergio Nasi.

2001-2002 Postdoctoral fellow at the Cancer Research Institute, UCSF. PI: Prof. Gerard Evan.

1998-2001 PhD student at the Centre for Nucleic Acids, CNR, University La Sapienza, Rome, Italy.

1997-1998 Biologist at the Centre for Nucleic Acids, CNR, University La Sapienza.

Awards and Grants, current

- Grant “Colaboración Publico-Privado” from the Spanish Ministry of Sciences, Innovation and Universities to the laboratory and Peptomyc. Title: “Clinical proof-of-concept of a first-in-class MYC inhibitor in combination therapy and expansion of its development plan (CLINIMYC)”. 2023-2026. 4.344.738€ (.531.343,40€ granted to Soucek’s laboratory and 2.632.633,35€ as soft loan to Peptomyc). PI: Laura Soucek.
- EIC Accelerator funding program under Horizon Europe to Peptomyc. “First-in-class MYC inhibitor: the making of a breakthrough cancer therapy”. 2023-2025. Blended finance ca. 5.000.000€ (2.494.504€ grant + 2.500.000€ equity). Main contact: Laura Soucek.
- SGR-Cat Grant for Consolidated Research Group of Catalunya from the Agency for Management of University and Research Grants (AGAUR). 2023-2025. 60.000€. PI: Laura Soucek
- M. Chiara Giorgetti Award from the Spanish Association of Metastatic Breast Cancer. Title: “Combining MYC and PARP inhibitors as a novel therapeutic strategy against triple-negative breast cancer”. 2022-2024. 130.000 €. PI: Laura Soucek
- 2nd BBVA Foundation Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI II), VHIO-FBBVA Collaboration. Title: “Understanding the tumor microenvironment to identify therapeutic targets and improve the response to immune checkpoint inhibitors” and “Understanding the mechanisms of resistance to IT and immune evasion to targeted therapies and designing new rational combinatory treatments”. 2022-2025. 30.000 €/year to Soucek’s laboratory. PI: Laura Soucek
- Grant “I+D+I en Líneas Estratégicas en colaboración público-privada” from the Spanish Ministry of Economy, Industry and Competitiveness. Title: “Using MYC inhibition to overcome immunotherapy resistance in KRAS-driven NSCLC with diverse mutational profiles (MYCOMBIO)”. 2021-2024. 399.771€ granted to Soucek’s laboratory and 377.537€ as soft loan to Peptomyc. PI: Laura Soucek
- Instituto de Salud Carlos III: Proyectos FIS de Investigación en Salud. Title: “Validation of new anti-Myc therapy in Melanoma”. 2020-2023. 255.000 €. PI: Laura Soucek
- Fundació La Marató de TV3. Title: “Overcoming immunotherapeutic resistance through Myc inhibition in KRas-driven NSCLC with diverse mutational landscape”. 2020-2023. 300.000 €. Project Director: Laura Soucek. Co-participant: Silvestre Vicent Cambra.

Awards and Grants, previous

- Grant “Retos de Colaboración” from the Spanish Ministry of Economy, Industry and Competitiveness. Title: “Identification of clinical biormakers of response to MYC inhibition in cancer treatment”. 2020-2023. 688.225,48€ granted to Soucek’s laboratory and 1.293.695,64€ as soft loan to Peptomyc. PI: Laura Soucek
- SME Instrument Phase II to Peptomyc from the European Commission. “Innovative cancer therapy through Myc inhibition: taking OMO-103 to market”. 2019-2023. 2.219.553,52€. Main contact: Laura Soucek.
- Canadian Institutes of Health Research Grant. Title: “Development of cancer therapies targeting Myc with cell penetrating b-HLH-LZ domains”. 2018-2023. 765.000,00 Canadian $ (85.000 granted to Soucek’s laboratory). Role: Co-applicant.
- H2020 INFRAIA 2017 Grant: “EDIReX: EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts”. 2018-2023. 5.156.198,75€. Role: Co-applicant (33.500€ for Soucek’s lab).

- EMPRESA NACIONAL DE INNOVACIÓN, S.A. (ENISA) Soft Loan to Peptomyc S.L.. 2018-2021. 300.000 €. Project director: Laura Soucek.
- ERC (European Commission) Proof-of-Concept Grant. Title: “Development of an effective and safe systemic Myc inhibitor for the treatment of multiple cancer types”. 2017-2019. 148.875€. PI: Laura Soucek
- APC grant to Peptomyc from the Ministry of Economy, Innovation and Competitiveness- 2017-2019. 15.000€. PI: Laura Soucek
- Catapult Award to Peptomyc from EIT (European Institute of Innovation and Technology) Health. 2018. 5000€ in Mentoring sessions. PI: Laura Soucek
- Instituto de Salud Carlos III: Proyectos FIS de Investigación en Salud. Title: “In vivo validation of innovative anti-Myc therapies in glioblastoma”. 2016-2019. 171.215€. PI: Laura Soucek
- Peptomyc received a grant from the Catalan Agency for Trade and Investment (ACCIÓ), for the project “Pre-clinical development of OmomycCPP: characterization of the immune response”. 2016-2018. 50,000€. PI: Laura Soucek
- Laura received the 2019 Award by the international Foundation of Women Entrepreneurs (FIDEM) for the Science category.
- NEOTEC grant to Peptomyc from the Ministry of Economy, Innovation and Competitiveness- 2017-2019. 212.410,23€. PI: Laura Soucek
- ERC (European Commission) Consolidator Grant. Title: “Pushing Myc inhibition towards the clinic”. 2014-2019. 1.730.700,00 €. PI: Laura Soucek
- European Woman Entrepreneur Award by the European Association of Economy and Competitiveness, Madrid, Spain. 15th March 2019.
- Winner of the Biofit 2018 Start Up Slam, Lille, France. December 2018.
- EIT (European Institute of Innovation and Technology) Public Award (chosen among 38 nominees across Europe and more that 8000 online votes) to Laura Soucek. October 2018, Budapest, Hungary.
- 2018 EmprenedorXXI Award to Laura Soucek as CEO of Peptomyc, for most innovative Start-up in 2017, Barcelona, Spain.
- Head Start Grant to Peptomyc from EIT (European Institute of Innovation and Technology) Health. 2017-2018. 45.000€. PI: Laura Soucek
- Winner of J&J Start Up Slam at BioEurope 2017, for best Start Up. Barcelona, Spain.
- Grant “Retos de Colaboración” from the Spanish Ministry of Economy, Industry and Competitiveness. Title: Preclinical development of Omomyc-CPP as a therapy for cancer treatment”. 2016-2018. 596.703,50€ granted to Soucek’s laboratory and 804.863,13€ as soft loan to Peptomyc. PI: Laura Soucek
- SME Instrument Phase I to Peptomyc from the European Commission. “Feasibility study of a novel treatment for cancer based on a recombinant peptide therapy”. 2015-2016. 50.000 euros. Main contact: Laura Soucek.
- BBVA Foundation Grant in Biomedicine. Title: “Validation of an innovative anti-Myc therapy in glioblastoma”. 2015-2017. 149.952€. PI: Laura Soucek
- FERO fellowship for a nanotechnology project: “Treating metastatic breast cancer with Omomyc-based nanoparticles”. 2015-2016. 32.000€. PI: Laura Soucek

- Grant for Emerging Research Group of Catalunya from the Agency for Management of University and Research Grants (AGAUR). 2014-2016. 16.500€. PI: Laura Soucek
- ERC (European Commission) Proof-of-Concept Grant. Title: “Developing an anti-Myc cell-penetrating peptide for cancer treatment”. 2016-2017. 147.750€. PI: Laura Soucek
- Instituto de Salud Carlos III: Proyectos FIS de Investigación en Salud. Title: “Advancing Myc inhibition towards the clinic for the treatment of lung cancer”. 2014-2017. 69.575,00 €. PI: Laura Soucek
- Association for International Cancer Research (AICR) Grant. Title: "Advancing Myc inhibition towards the clinic: characterization of an Omomyc cell-penetrating peptide". 2013-2016. £170.357,00. PI: Laura Soucek
- First prize in the Competition for Innovation by VHIR, Barcelona, Spain. Title: “Pushing Myc inhibition to the clinic using cell penetrating peptides”. The project aims at developing a new therapeutic option for patients with cancer by targeting Myc protein with an inhibitor peptide, Omomyc, a new pharmaceutical entity. 2015. 5.000€. PI: Laura Soucek
- Bayer “Grants4Targets” Initiative. Title: “Pushing Myc inhibition towards the clinic”. 2013-2014. 5.000€.PI: Laura Soucek
- MIGUEL SERVET fellowship (Fondo de Investigación Sanitaria, Instituto de Salud Carlos III). Title: “Inhibiting Myc and Myc dependent inflammatory response as cancer therapies”. 2011-2014. 273.375,00€ PI: Laura Soucek
- FERO FELLOWSHIP. Title: “Targeting Myc in tumors and microenvironment”. Competitive award to support scientists in cancer research. 2011-2013. 70.000€. PI: Laura Soucek
- Ramon y Cajal Fellowship (Highest score in the ranking) – The award had to be declined by Dr. Soucek because of conflict with the Miguel Servet Fellowship. 2010. PI: Laura Soucek
- Bear Necessities Pediatric Cancer Foundation: Grant awarded to support an outstanding young investigator in pediatric cancer research. Subject: Modeling Myc therapeutic potential in vivo. 2009. 40.000$. PI: Laura Soucek
- AACR award “Future Leaders, New directions” for outstanding early-career scientists in cancer research. This is a travel award to participate in a special symposium created in 2007 at the request of Dr. Geoffrey M.Wahl, then President of the AACR, to showcase the best and brightest among trainee researchers in the cancer fields. 2008.
- Post-doctoral Teaching Fellowship, UCSF: Molecular Biology Small Group Teaching to 2nd year Medical students at UCSF in “Cancer: Bench to Bedside (CBB)” block, Fall 2007.
- Keystone Symposia scholarship to attend the meeting “Mechanisms Linking Inflammation and Cancer” in Santa Fe, NM, February 10 - February 15, 2007
- Research fellowship from Fondazione Adriano Buzzati-Traverso, Rome, Italy: Competitive award for Postdoctoral students in Cancer Biology. The aim of this project was to investigate the role of Myc as both a transcriptional activator and repressor. 2002
- Postdoctoral CNR fellowship, Rome, Italy: Competitive award meant to cover the salary of young investigators willing to gain research experience in a foreign country. The fellowship was used by the recipient to work for 16 months at the Cancer Research Institute of UCSF on mouse models of Cancer. The aim of this project was to build two different mouse models expressing a Myc dominant negative transgene, Omomyc. 2001.
- Research fellowship from Associazione Italiana Ricerca sul Cancro (AIRC), Rome, Italy: Competitive award for young investigators in Cancer Biology. The aim of this project was to study the effect of interfering with Myc function on chromatin structure. PI: Sergio Nasi. 2001

- Centro Nazionale di Ricerca (CNR) fellowship for PhD students, Rome, Italy: Competitive award for Students in the Genetics and Molecular Biology PhD Program. The aim of this project was to design a dominant negative of c-Myc, Omomyc, to be used in tumor cell lines. 1998.
- Research fellowship for graduate students from the Fondazione Adriano Buzzati-Traverso, Rome, Italy: Competitive Pre-Doctoral award in Cancer Biology. The main aim of this project was to investigate the dimerization specificity of bHLHZip proteins, with particular attention to Myc and Max. 1997.
- Agenzia per il DIritto agli Studi Universitari (ADISU) Recognition Award for best students in Mathematical, Physical and Natural Sciences, Rome, Italy. 1995

Peer-reviewed publications

1. Casacuberta-Serra S, Gonzalez-Larreategui I, Capitán-Leo D and **Soucek L**. MYC and KRAS Cooperation: From Historical Challenges to Therapeutic Opportunities in Lung Cancer. Under revision. Review.

2. Jonathan R. Whitfield and **Laura Soucek**. MYC in cancer: from undruggable target to clinical trials. Nat Rev Drug Disc. Under revision. Review.

3. Mariano F. Zacarías-Fluck, **Laura Soucek***, and Jonathan R. Whitfield. MYC: there is more to it than cancer. Frontiers Cell & Dev Biol. Under revision. Review. ***Corresponding author**.

4. Sandra Bibbo', Emily Capone, Sara Ponziani, Alessia Lamolinara, Manuela Iezzi, Rossano Lattanzio, Katia Mazzocco, Martina Morini, Francesco Giansanti, Vincenzo De Laurenzi, Jonathan Whitfield, Stefano Iacobelli, Rodolfo Ippoliti, Marie-Eve Beaulieu, Laura Soucek, Arturo Sala and Gianluca Sala. EV20/Omomyc: a novel dual MYC/HER-3 targeting immunoconjugate. Under revision. Article. ***Corresponding author**.

5. Hugo Thabussot, Marie-Beaulieu and **Laura Soucek**. Stretching the Limits of Bicyclic Peptides: A Novel Approach to MYC Inhibition and Beyond. GEN Biotechnology. In press. News and Views.

6. Elena Garralda, Marie-Eve Beaulieu, Víctor Moreno, Sílvia Casacuberta-Serra, Sandra Martínez-Martín, Laia Foradada, Guzman Alonso, Daniel Massó-Vallés, Sergio López-Estévez, Toni Jauset, Elena Corral, Bernard Doger, Tatiana Hernández, Raquel Perez-Lopez, Oriol Arqués, Virginia Castillo Cano, Josefa Morales, Manuela Niewel, **Laura Soucek*** and Emiliano Calvo. MYC-targeting by OMO-103 in solid tumours: a phase 1 trial. Nature Medicine. doi: 10.1038/s41591-024-02805-1. Article. ***Corresponding author**.

7. Casacuberta-Serra S, Gonzalez-Larreategui I, **Soucek L**. eIF4A dependency: the hidden key to unlock KRAS mutant non-small cell lung cancer's vulnerability. Transl Lung Cancer Res 2023;12(12):2570-2575. doi: 10.21037/tlcr-23-682. Editorial commentary.

8. Sandra Martínez-Martín, Marie-Eve Beaulieu and **Laura Soucek**. MYC inhibition in lymphoma: lessons learnt and future directions. Cancer Drug Resist 2023; 6:205-22 doi: 10.20517/cdr.2022.127. Review.

9. Mariano F. Zacarías-Fluck, Daniel Massó-Vallés, Fabio Giuntini, Íñigo González-Larreategui, Jastrinjan Kaur, Sílvia Casacuberta-Serra, Toni Jauset, Sandra Martínez-Martín, Génesis Martín-Fernández, Erika Serrano del Pozo, Laia Foradada Felip, Judit Grueso, Lara Nonell, Marie-Eve Beaulieu, Jonathan R. Whitfield, **Laura Soucek**. Reducing MYC's transcriptional

footprint unveils a good prognostic gene signature in melanoma. Genes & Dev. Published in Advance April 6, 2023, doi:10.1101/gad.350078.122. Article.

10. Marie-Eve Beaulieu, Sandra Martínez-Martín, Jastrinjan Kaur, Virginia Castillo Cano, Daniel Massó-Vallés, Laia Foradada Felip, Sergio López-Estévez, Erika Serrano del Pozo, Hugo Thabussot and **Laura Soucek**. Pharmacokinetic analysis of Omomyc shows lasting structural integrity and long terminal half-life in tumor tissue. Cancers. 2023. 15, 826. https://doi.org/10.3390/cancers15030826. Communication.

11. Jastrinjan Kaur and **Laura Soucek**. Going for a “KDIP” in colorectal cancer treatment. Clinical and Translational Discovery 2022. doi.org/10.1002/ctd2.108. Commentary.

12. Daniel Massó-Vallés, Marie-Eve Beaulieu, Toni Jauset, Fabio Giuntini, Mariano F. Zacarías-Fluck, Laia Foradada, Sandra Martínez-Martín, Erika Serrano, Génesis Martín-Fernández, Sílvia Casacuberta-Serra, Virginia Castillo Cano, Jastrinjan Kaur, Sergio López-Estévez, Miguel Ángel Morcillo, Mohammad Alzrigat, Loay Mahmoud, Antonio Luque-García, Marta Escorihuela, Marta Guzman, Joaquín Arribas, Violeta Serra, Lars-Gunnar Larsson, Jonathan R. Whitfield & **Laura Soucek**. MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. Cancer Res Comm 2022. 2 (2): 110–130. doi.org/10.1158/2767-9764.CRC-21-0103. Article.

13. Chiara Pighi, Taek-Chin Cheong, Mara Compagno, Enrico Patrucco, Maddalena Arigoni, Martina Olivero, Qi Wang, Cristina López, Stephan H. Bernhart, Bruno M. Grande, Teresa Poggio, Fernanda Langellotto, Lisa Bonello, Riccardo Dall’Olio, Sandra Martínez-Martín, Luca Molinaro, Paola Francia di Celle, Jonathan R. Whitfield, **Laura Soucek**, Claudia Voena, Raffaele Calogero, Ryan D. Morin, Louis M. Staudt, Reiner Siebert, Alberto Zamò, Roberto Chiarle. Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. Blood Advances 2021. doi: 10.1182/bloodadvances.2021005682. Article.

14. Martínez-Martín S, **Soucek** L. MYC inhibitors in multiple myeloma. Cancer Drug Resist 2021 Aug 13;4(4):842-865. doi: 10.20517/cdr.2021.55. Review.

15. Jonathan R. Whitfield & **Laura Soucek.** The long journey to bring a Myc inhibitor to the clinic. J Cell Biol. 2021. Aug 2;220(8):e202103090. doi: 10.1083/jcb.202103090. Review.

16. Jonathan R. Whitfield & **Laura Soucek**. An “-omics” toolbox to study MYC. Methods Mol Biol. 2021;2318:1-11. doi: 10.1007/978-1-0716-1476-1_1. Book chapter.

17. Mariano F. Zacarías-Fluck, Toni Jauset, Sandra Martínez-Martín, Jastrinjan Kaur, Sílvia Casacuberta-Serra, Daniel Massó-Vallés, Erika Serrano del Pozo, Génesis Martín-Fernández, Íñigo González-Larreategui, Sergio López-Estévez, Lamorna Brown-Swigart, Marie-Eve Beaulieu, Jonathan R. Whitfield, Babita Madan, David M. Virshu4, Gerard I. Evan and **Laura Soucek**. The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets. Life Sci Alliance. 2021 Mar;4(5). DOI: 10.26508/lsa.2019004902021. Article.

18. Paola Pellanda, Mattia Dalsass, Marco Filipuzzi, Alessia Loffreda, Alessandro Verrecchia, Virginia Castillo Cano, Hugo Thabussot, Mirko Doni, Marco J. Morelli, **Laura Soucek**, Theresia Kress, Davide Mazza, Marina Mapelli, Marie-Eve Beaulieu, Bruno Amati and Arianna Sabò. Integrated requirement of non-specific and sequence-specific DNA binding in MYC-driven transcription. EMBO J. 2021. DOI: 10.15252/embj.2020105464. Article.

19. Beaulieu ME, Castillo F, **Soucek L.** Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein. Cells. 2020 Apr 22;9(4). pii: E1038. doi: 10.3390/cells9041038. Review.

20. Massó-Vallés D. and **Soucek L.** Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc. Cells. 2020, 9, 883; doi:10.3390/cells9040883. Review.

21. Daniel Massó-Vallés, Marie-Eve Beaulieu and **Laura Soucek**. "MYC, MYCL and MYCN as therapeutic targets in lung cancer". Expert Opin Ther Targets. 2020 Jan 31. doi: 10.1080/14728222.2020.1723548. Review.

22. Nicole Sodir, Roderik Kortlever, Valentin Barthet, Tania Campos, Luca Pellegrinet, Steven Kupczak, Panayiotis Anastasiou, Lamorna Brown-Swigart, **Laura Soucek**, Mark Arends, Trevor Littlewood, and Gerard Evan. "Myc instructs and maintains pancreatic adenocarcinoma phenotype". Cancer Discov. 2020 Jan 15. pii: CD-19-0435. doi: 10.1158/2159-8290.CD-19-0435. Article.

23. Rafael Ikemori, Marta Gabasa, Paula Duch, Miguel Vizoso, Paloma Bragado, Marselina Arshakyan, Iuliana-Cristiana Luis, Albert Marín, Sebastian Morán, Manuel Castro, Gemma Fuster, Sabrina Gea-Sorli, Toni Jauset, **Laura Soucek**, Luis Montuenga, Manel Esteller, Eduard Monsó, Víctor Ivo Peinado, Pere Gascón, Cristina Fillat, Frank Hilberg, Noemí Reguart, Jordi Alcaraz. "Epigenetic SMAD3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma". Cancer Res. 2020 Jan 15;80(2):276-290. doi: 10.1158/0008-5472.CAN-19-0637. Article.

24. Mireia Pesarrodona, Toni Jauset, Zamira V. Díaz-Riascos, Alejandro Sánchez-Chardi, Marie-Eve Beaulieu, Joaquin Seras-Franzoso, Laura Sánchez-García, Ricardo Baltà-Foix, Sandra Mancilla, Yolanda Fernández, Ursula Rinas, Simó Schwartz Jr, **Laura Soucek**, Antonio Villaverde, Ibane Abasolo, and Esther Vázquez. "Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies". Advanced Sciences. Adv Sci (Weinh). 2019 Jul 24;6(18):1900849. doi: 10.1002/advs.201900849. Article.

25. Jonathan R. Whitfield and **Laura Soucek**. Editorial Overview: Peptides in Cancer. Current Opinion in Pharmacology. 2019 Jun 27. pii: S1471-4892(19)30045-1. Doi: 10.1016/j.coph.2019.06.001. Editorial.

26. Marie-Eve Beaulieu and **Laura Soucek**. Finding MYCure. Mol Cell Oncology. 2019. Doi: 10.1080/23723556.2019.1618178. Author's View.

27. Ramón Y Cajal S, Sancho P, **Soucek L**, Peinado H, Abad M, Valiente M, Efeyan A, Pardo J, Quesada V, Jimeno J, Duque PM, Antón A, Varela I, Schuhmacher AJ. A spotlight on cancer researchers in Spain: new paradigms and disruptive ideas. Clin Transl Oncol. 2019 Aug 9. doi: 10.1007/s12094-019-02199-4. Article.

28. Marie-Eve Beaulieu, Toni Jauset, Daniel Massó-Vallés, Sandra Martínez-Martín, Peter Rahl, Loïka Maltais, Mariano F. Zacarias-Fluck, Sílvia Casacuberta-Serra, Erika Serrano del Pozo, Christopher Fiore, Laia Foradada, Virginia Castillo Cano, Matthew Guenther, Eduardo Romero Sanz, Marta Oteo, Cynthia Tremblay, Génesis Martín, Danny Letourneau, Martin Montagne, Miguel Ángel Morcillo Alonso, Jonathan R. Whitfield, Pierre Lavigne and **Laura Soucek**. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-Myc therapy. Sci Trans Med. 2019 Mar 20;11(484). Doi: 10.1126/scitranslmed.aar5012. Article.

29. Irina Alimova, Angela Pierce, Etienne Danis, Andrew Donson, Diane K Birks, Andrea Griesinger, Nicholas K Foreman, Mariarita Santi, **Laura Soucek**, Sujatha Venkataraman & Rajeev Vibhakar. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1 deficient Group 2 Atypical Teratoid Rhabdoid Tumors to suppress tumor growth in vivo. Int J Cancer. 2019 Apr 15;144(8):1983-1995. doi: 10.1002/ijc.31873. Article.

30. Sílvia Casacuberta-Serra and **Laura Soucek.** Myc and Ras, the Bonnie and Clyde of immune evasion. Translational Cancer Research. 2018 Feb ;7(Suppl 4):S457-S459. doi: 10.21037/tcr.2018.03.09. Editorial.

31. Toni Jauset, Daniel Massó-Vallés, Sandra Martínez-Martín, Marie-Eve Beaulieu, Laia Foradada, Francesco Paolo Fiorentino, Jun Yokota, Bernard Haendler, Stephan Siegel, Jonathan R. Whitfield and **Laura Soucek**. BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC. Oncotarget. 2018 Apr 10;9(27):18734-18746. doi: 10.18632/oncotarget.24648. Article.

32. Chi Dang, E Premkumar Reddy, Kevan Shokat, and **Laura Soucek**. Drugging the 'undruggable' cancer targets. Nat Rev Cancer. 2017 Jun 23. doi: 10.1038/nrc.2017.36. Review.

33. Kim Pedersen, Faiz Bilal, Cristina Bernadó Morales, Maria Teresa Salcedo, Teresa Macarulla, Daniel Massó-Vallés, Vishnu Mohan, Ana Vivanco, Maria-Josep Carreras, Xavier Serres, Monder Abu-Suboh, Joaquim Balsells, Elena Allende, Irit Sagi, **Laura Soucek**, Josep Tabernero and Joaquín Arribas. Pancreatic cancer heterogeneity and response to Mek inhibition. Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.174. Article.

34. Loïka Maltais, Martin Montagne, Mikaël Bédard, Cynthia Tremblay, **Laura Soucek** and Pierre Lavigne. Biophysical Characterization of the b-HLH-LZ of ΔMax, an Alternatively Spliced Isoform of Max Found in Tumor Cells: Towards the Validation of a Tumor Suppressor Role for the Max Homodimer. PLoS One. 2017 Mar 28; 12(3): e0174413. https://doi.org/10.1371/journal.pone.0174413. Article.

35. Jonathan R Whitfield, Marie-Eve Beaulieu, **Laura Soucek**. Strategies to inhibit Myc and their clinical applicability. Front. Cell Dev. Biol., 23 February 2017. https://doi.org/10.3389/fcell.2017.00010. Review.

36. Annette T. Byrne, Denis G. Alférez, Frederic Amant, Daniela Annibali, Joaquín Arribas, Andrew V. Biankin, Alejandra Bruna, Eva Budinská, Carlos Caldas, David K. Chang, Robert B. Clarke, Hans Clevers, George Coukos, Virginie Dangles-Marie, S. Gail Eckhard, Eva Gonzalez-Suarez, Els Hermans, Manuel Hidalgo, Monika Jarzabek, Steven de Jong, Jos Jonkers, Kristel Kemper, Luisa Lanfrancone, Gunhild Mari Mælandsmo, Elisabetta Marangoni, Jean-Christophe Marine, Enzo Medico, Jens Henrik Norum, Héctor G. Palmer, Daniel S. Peeper, Pier Giuseppe Pelicci, Alejandro Piris, Sergio Roman-Roman, Oscar M. Rueda, Joan Seoane, Violeta Serra, **Laura Soucek**, Dominique Vanhecke, Alberto Villanueva, Emilie Vinolo, Andrea Bertotti and Livio Trusolino. Interrogating open issues in cancer precision medicine using Patient-Derived Xenograft Models. Nat Rev Cancer. 2017 Jan 20. doi: 10.1038/nrc.2016.140. Review.

37. M.E. Beaulieu, T. Jauset, D. Massó-Vallés, **L. Soucek*** and J.R. Whitfield. Mouse Models in Personalized Cancer Medicine. Chapter 6 of Cancer genetics and Genomics for Personalized Medicine. 2017. ISBN: 9789814669887. Book Chapter. ***Corresponding author**.

38. **Soucek L**, Torrens L, Pujades C and Claría J. Experimental Models. Handbook of Translational Medicine. Medica UB. 2016. ISBN: 978-84-475-4030-3. Book chapter.

39. Daniel Massó-Vallés, Toni Jauset and **Laura Soucek**. Ibrutinib repurposing: from B cell malignancies to solid tumors. Oncoscience. 2016 Jun 10;3(5-6):147-8. DOI: 10.18632/oncoscience.310. Review.

40. Francesco Paolo Fiorentino, Elvan Tokgün, Sònia Solé-Sánchez, Sabrina Giampaolo, Onur Tokgün, Toni Jauset, Takashi Kohno, Manuel Perucho, **Laura Soucek**, Jun Yokota. Growth Suppression by MYC Inhibition in Small Cell Lung Cancer Cells with TP53 and RB1 Inactivation. Oncotarget. 2016 Apr 18. doi: 10.18632/oncotarget.8826. [Epub ahead of print] Article.

41. Cecconi F, **Soucek L**, Taub DD, Ziparo E. Live or Die: Choice Mechanisms in Stressed Cells. Mediators Inflamm. 2015; 2015:454863. Epub 2015 Oct 8. Editorial.

42. William H. Goodson III, Leroy Lowe, David O. Carpenter, Michael Gilbertson, Abdul Manaf Ali, Adela Lopez de Cerain Salsamendi, […], **Laura Soucek**, […], Zhiwei Hu. Assessing the Carcinogenic Potential of Low Dose Exposures to Chemical Mixtures in the Environment: The Challenge Ahead. Carcinogenesis. 2015 Jun;36 Suppl 1:S254-96. doi: 10.1093/carcin/bgv039. Review.

43. Stephanie C. Casey, Monica Vaccari, Fahd Al-Mulla, Rabeah Al-Temaimi, Amedeo Amedei, Mary Helen Barcellos-Hoff, Dustin Brown, Marion Chapellier, […], Sandra Ryeom, Hosni K. Salem, Ivana Scovassi, Neetu Singh, **Laura Soucek**, Louis Vermeulen, Jonathan R. Whitfield, Jordan Woodrick, Annamaria Colacci, William H. Bisson, and Dean W. Felsher. Assessing the Carcinogenic Potential of Environmental Chemicals: The Tumor Microenvironment. Carcinogenesis. 2015 Jun;36 Suppl 1:S160-83. doi: 10.1093/carcin/bgv035. Review.

44. Daniel Massó-Vallés, Toni Jauset, Erika Serrano, Nicole M. Sodir, Kim Pedersen, Nesrine I. Affara, Jonathan R. Whitfield, Marie-Eve Beaulieu, Gerard I. Evan, Laurence Elias, Joaquín Arribas and **Laura Soucek**. Ibrutinib exerts potent anti-fibrotic and anti-tumor activity in mouse transgenic and patient derived xenograft models of pancreatic adenocarcinoma. Cancer Res. 2015 Apr 15; 75(8): 1675-1681. Article.

45. Whitfield J, Littlewood T, Evan GI, **Soucek L**. The estrogen receptor fusion system in mouse models: a reversible switch. Cold Spring Harb Protoc. 2015 Mar 2;2015(3):pdb.top069815. doi: 10.1101/pdb.top069815. Book chapter.

46. Whitfield J, Littlewood T, **Soucek L.** Tamoxifen administration to mice. Cold Spring Harb Protoc. 2015 Mar 2;2015(3):pdb.prot077966. doi: 10.1101/pdb.prot077966. Book chapter.

47. Daniela Annibali, Jonathan R Whitfield, Emilia Favuzzi, Toni Jauset, Erika Serrano, Isabel Cuartas, Sara Redondo-Campos, Gerard Folch, Alba Gonzàlez-Juncà, Nicole M Sodir, Daniel Massó-Vallés, Marie-Eve Beaulieu, Lamorna B Swigart, Margaret M Mc Gee, Maria Patrizia Somma, Sergio Nasi, Joan Seoane, Gerard I Evan, and **Laura Soucek**. Myc Inhibition as a Therapeutic Strategy Against Glioma: a Role for Myc in Proficient Mitosis. Nat Communications. 2014 Aug 18;5:4632. doi: 10.1038/ncomms5632. Article.

48. Book: “The Myc gene”, Methods and Protocols, Series: Methods in Molecular Biology, Vol. 1012. **Soucek, Laura**; Sodir, Nicole M. (Editors) 2013. A product of Humana Press.

49. Nicole M. Sodir and **Laura Soucek**. Chapter: The Myc world within reach. “Myc: Methods and Protocols” Book, Methods Mol Biol. 2013;1012:1-6. Book chapter.

50. **Laura Soucek**, Jonathan R. Whitfield, Nicole M. Sodir, Daniel Massó-Vallés, Erika Serrano, Anthony N. Karnezis, Lamorna Brown Swigart and Gerard I. Evan. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 2013 Mar 1;27(5):504-13. Article.

51. Whitfield J, **Soucek L.** Tumor microenvironment: becoming sick of Myc. Cell Mol Life Sci. 2012, 69(6), 931-934. Review.

52. Oscar M. Pello, Maria De Pizzol, Massimiliano Mirolo, **Laura Soucek**, Luca Zammataro, Angelo Amabile, Andrea Doni, Lamorna B. Swigart, Gerard I. Evan, Alberto Mantovani, Massimo Locati. c-Myc controls alternative activation of human macrophages and tumor-associated macrophage biology. Blood. 2012, 119(2), 411-421. Article.

53. **Laura Soucek**, Joseph J Buggy, Roderik Kortlever, Shanthi Adimoolam, Lamorna Brown Swigart and Gerard Evan. Modeling mast cell inhibition by PCI-32765 as potential therapy for insulinoma. Neoplasia. 2011; 13(11):1093–100. Article.

54. Mauro Savino, Daniela Annibali, Nicoletta Carucci, **Laura Soucek**, Gerard Evan, Sergio Nasi. The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy. PLoS One. 2011;6(7):e22284. Epub 2011 Jul 21. Article.

55. Nicole M Sodir, Lamorna Brown Swigart, Anthony N Karnezis, Douglas Hanahan, Gerard Evan and **Laura Soucek.** Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011 May 1;25(9):907-16. Epub 2011 Apr 8. Article.

56. Fukazawa T, Maeda Y, Matsuoka J, Yamatsuji T, Shigemitsu K, Morita I, Faiola F, Durbin ML, **Soucek L**, Naomoto Y. Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc. Anticancer Res. 2010 Oct;30(10):4193-200. Article.

57. **Soucek L**, Evan GI. The ups and downs of Myc biology. Curr Opin Genet Dev. 2010 Feb;20(1):91-95. Epub 2009 Dec 3. Review.

58. Andrew Finch*, **Laura Soucek***, Melissa Junttila, Lamorna Brown Swigart and Gerard I. Evan. Acute over-expression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/β-catenin pathway activation. Mol Cell Biol. 2009 Oct;29(19):5306-15. Epub 2009 Jul 27. Article. ***Joint first authors**

59. **Laura Soucek**, Jonathan Whitfield, Carla P. Martins, Andrew J. Finch, Nicole M. Sodir, Lamorna Brown Swigart, Sergio Nasi and Gerard I. Evan. Modelling Myc inhibition as a cancer therapy. Nature. 2008 Oct 2;455(7213):679-83. Epub 2008 Aug 17. Article.

60. **Soucek L**, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007 Oct;13(10):1211-8. Epub 2007 Sep 30. Article.

61. Finch A, Prescott J, Shchors K, Hunt A, **Soucek L**, Dansen TB, Swigart LB, Evan GI. Bcl-x(L) gain of function and p19(ARF) loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms. Cancer Cell. 2006 Aug;10(2):113-120. Article.

62. Elizabeth R. Lawlor, **Laura Soucek,** Lamorna Brown-Swigart, Ksenya Shchors, Uli Bialucha, Gerard I. Evan. Reversible Kinetic Analysis of Myc Targets In vivo Provides Novel Insights into Myc-Mediated Tumorigenesis. Cancer Res. 2006 May 1;66(9):4591-601. Article.

63. Maria A. Christophorou, Dionisio Martin-Zanca, **Laura Soucek**, Elizabeth Lawlor, Emmy Verschuren, Lamorna Brown-Swigart and Gerard I. Evan. Temporal dissection of p53 function in vitro and in vivo. Nature Genetics. 2005 Jul;37(7):718-26. Article.

64. **Laura Soucek,** Sergio Nasi, and Gerard Evan. Omomyc expression in skin prevents Myc-induced papillomatosis. Cell Death Differ. 2004 Sep;11(9):1038-45. Article.

65. Satoshi Kanasawa, **Laura Soucek,** Gerard Evan, Takashi Okamoto, and B. Matija Peterlin. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene. 2003 Aug 28;22(36):5707-11. Article.

66. **Laura Soucek** and Gerard Evan. Myc – is this the oncogene from Hell? Cancer Cell. 2002 June; 1(5): 406-408. Review.

67. **Laura Soucek**, Richard Jucker, Laura Panacchia, Ruggero Ricordy, Franco Tatò, and Sergio Nasi. Omomyc, a Potential Myc Dominant Negative, Enhances Myc-induced Apoptosis. Cancer Res. 2002; 62: 3507-3510. Article.

68. Mandolesi G, Gargano S, Pennuto M, Illi B, Molfetta R, **Soucek L,** Mosca L, Levi A, Jucker R, Nasi S. NGF-dependent and tissue-specific transcription of vgf is regulated by a CREB-p300 and bHLH factor interaction. FEBS Lett. 2002. ¡ 510(1-2):50-6. Article.

69. Sergio Nasi, Roberta Ciarapica, Richard Jucker, Jessica Rosati and **Laura Soucek.** Making decisions through Myc. FEBS. 2001. 490(3): 153-162. Review.

70. Sergio Nasi and **Laura Soucek**. p53 Gene e Proteina, Enciclopedia Medica Italiana, Tomo III, 2000, 4313-4323. Book chapter.

71. **Soucek L.**, Citterich M.H., Sacco A., Jucker R., Cesareni G. and Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene. 1998, 17(19): 2463-2472. Article.

Professional organizations

Since 2021 SEBBM (Spanish Society of Biochemistry and Molecular Biology)

Since 2011 ASEICA (Spanish Association for Cancer Research)

Since 2008 AACR (American Association for Cancer Research)

Since 2008 WICR (AACR-Women in Cancer Research)

2006-2011 AAAS (The American Association for the Advancement of Science)

Keywords, Areas of Interest

Cancer, MYC, oncogenes, tumor suppressors, apoptosis, p53, mouse models, inflammation, cell culture, pancreas, skin, intestine, liver, lung, senescence, cell cycle, molecular modeling,

protein structure, mutagenesis, protein-protein interaction, transgenic mice, peptide therapeutics, tumor microenvironment.

Service to Professional Publications

Since 2021 Member of the Editorial Advisory Board of GEN Biotechnology.

Since 2021: Review Editor in Frontiers in Oncology - Molecular and Cellular Oncology.

2021 Editor of the book “The Myc gene: methods and protocols” of the Series “Methods in Molecular Biology”, Part of the Methods in Molecular Biology book series (MIMB, volume 2318).

2019-2021 Editor of the second edition of the book “The Myc gene: methods and protocols” of the Series “Methods in Molecular Biology”, a product of Humana Press to be published in 2020.

2019 Editor of the special issue “Cancer and Immunomodulation 2019” of Current Opinion in Pharmacology (COPHAR). Co-editors: Laura Soucek, Jonathan Whitfield, Di Virgilio Francesco, Pelegrin Pablo.

Since 2014: Scientific Editor for Cancer Discovery.

2012 Editor of the book “The MYC gene: methods and protocols” of the Series “Methods in Molecular Biology”, a product of Humana Press.

Reviewer for:

Anti-cancer Drugs, BBA (Biochimica et Biophysica Acta), BioDrugs, BioEssays, Cancer Discovery, Cancer Immunology and Immunotherapy, Cancer Immunology Research, Cancer Research, Cancer Research Communications, Cancer Treatment Reviews, Cancers, Cell Chemical Biology, Cell Death & Disease, Clinical Cancer Research, Communications Biology, Current Pharmaceutical Design, Developmental Dynamics, Drug Discovery Today, E-Biomedicine, eLIFE, Frontiers in Cell and Developmental Biology, Frontiers in Oncology, Gastroenterology Research and Practice, GEN Biotechnology, Gut, International Journal of Biological Sciences, IJEP (International Journal of Experimental Pathology), Journal of Cellular Biochemistry (JCB), Journal of Experimental and Clinical Cancer Research, JoVE Peer Reviewed Scientific Video Journal – Methods and Protocols, Mammalian Genome, Medicinal Research Reviews, Molecular Biology and Evolution, Molecular Biology Reports, Molecular Oncology, Molecules, Nature, Nature Cell Biology, Nature Communications, Nature Medicine, Oncogene, Oncogenesis, “Oncology” books iConcept Press Ltd, Oncotarget, Peptide Science, Pharmacological Reviews, Plos One, Science Advances, Science Translational Medicine, Scientific Reports, Therapeutic Advances in Chronic Disease, Trends in Cancer, Tumor Biology.

Patents

June 2023 Application for European patent nº EP23382554. "COMBINATION THERAPY WITH BRAF INHIBITORS FOR THE TREATMENT OF CANCER ", presented by FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA VALL D'HEBRON and ICREA. Inventors: Mariano Zacarías-Fluck, Jastrinjan Kaur and Laura Soucek.

June 2023	Application for European patent nº EP23382553. "COMBINATION THERAPY WITH MEK INHIBITORS FOR THE TREATMENT OF CANCER", presented by FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA VALL D'HEBRON and ICREA. Inventors: Mariano Zacarías-Fluck, Jastrinjan Kaur and Laura Soucek.
June 2023	Application for European patent nº EP23382552. "COMBINATION THERAPY WITH KRAS INHIBITORS FOR THE TREATMENT OF CANCER", presented by FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA VALL D'HEBRON, ICREA and Peptomyc S.L.. Inventors: Sílvia Casacuberta-Serra, Marie-Eve Beaulieu, Laura Soucek, and Iñigo Gonzalez-Larrategui.
Abril 2023	Application for European patent nº EP23382345. "METHOD FOR ASSESSING OR MONITORING THE RESPONSE TO A CANCER TREATMENT", presented by Peptomyc S.L.. Inventors: Laura Soucek, Sílvia Casacuberta-Serra and Marie-Eve Beaulieu.
October 2022	Application for European patent nº EP22383028. “COMBINATION THERAPY FOR THE TREATMENT OF CANCER”, presented by FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA VALL D'HEBRON, ICREA and Peptomyc S.L.. Inventors: Laura Soucek, Daniel Massó-Vallés and Fabio Giuntini.
October 2022	Application for European patent nº EP22383031. “METHOD FOR PREDICTING RESPONSE TO A CANCER TREATMENT”, presented by Peptomyc S.L.. Inventors: Laura Soucek, Sílvia Casacuberta-Serra and Marie-Eve Beaulieu.
March 2019	Application for European patent nº EP19382194. “COMBINATION THERAPY FOR THE TREATMENT OF CANCER”, presented by FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA VALL D'HEBRON, ICREA and Peptomyc S.L.. Inventors: Laura Soucek, Sílvia Casacuberta-Serra and Marie-Eve Beaulieu.
March 2019	Application for European patent nº EP19382195. “METHODS FOR THE DIAGNOSIS OF LUNG CANCER”, presented by FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA VALL D'HEBRON, ICREA and Peptomyc S.L.. Inventors: Laura Soucek and Marie-Eve Beaulieu.
July 2016	Application for European patent nº EP16382339. "METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER", presented by FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA VALL D'HEBRON and ICREA. Inventors: Laura Soucek, Toni Jauset and Marie-Eve Beaulieu.
December 2014	Application for US patent: "METHODS FOR THE TREATMENT OF FIBROSIS”, presented by Pharmacyclics Inc. Inventors: Laura Soucek, Toni Jauset and Daniel Massó-Vallés. WIPO Patent Application WO/2016/090021
March 2013	Application for European patent nº EP13382167. "METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER", presented by FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA VALL D'HEBRON. Inventors: Laura Soucek and Marie-Eve Beaulieu.

Presentations and conferences, National and International

2024 Germans Trias I Pujol Research Institute Scientific Seminars. Title: “The long journey of a MYC inhibitor from the laboratory to clinical trials”. Badalona, Barcelona, Spain. Invited Speaker.

2024 VHIO Talks First Session: From the laboratory to the clinic. The importance of translational research. Public talk for the general audience. Barcelona, Spain. Invited Speaker.

2023 9th Symposium on Advances in Cancer Immunology and Immunotherapy, Athens, Greece. “Progress in the development of a clinically viable MYC inhibitor”. Invited speaker.

2023 FERO Scientific Retreat 2023, Madrid, Spain. “The development path of a drug from the laboratory to clinical trials”. Invited speaker.

2023 40th Anniversary ASEICA Congress; Round table “Entrepreneurship: Innovation from the benchside”. A Coruña, Spain. Invited panelist.

2023 4th Crick International Cancer Conference, The Francis Crick Institute, London, United Kingdom. Title: “Joys and pains of developing the first clinically viable MYC inhibitor". Invited speaker.

2023 16th Institute for Bioengineering of Catalonia (IBEC) Symposium on Bioengineering for future and precision medicine, Barcelona, Spain. Title: “Development of a first clinically viable MYC inhibitor for cancer treatment”. Keynote speaker.

2023 45th Congress of the Spanish Society of Biochemistry and Molecular Biology (SEBBM), Zaragoza, Spain. Entrepreneurship and Innovation Session Coordinator and Chair.

2023 CRUK Cambridge Centre Postgraduate Symposium 2023, Cambridge, United Kingdom. Title: “Development of a first clinically viable MYC inhibitor for cancer treatment”. Keynote speaker.

2023 Biomedicine Students Congress of the International University of Catalunya, San Cugat, Spain. Title: “Challenging dogmas: the difficult path to develop a MYC inhibitor for cancer treatment”. Invited Speaker.

2023 Princess Margaret Cancer Centre Seminar Series, Toronto, Canada. Title: “Development of a first clinically viable MYC inhibitor for cancer treatment”. Invited Speaker.

2023 EACR 2023 Congress: Innovative Cancer Science, Turin, Italy. Title: “Progress in the development of a clinically viable MYC inhibitor”. Poster presentation.

2023 AACR 2023 Annual Meeting. Orlando, USA. Minisymposium: Biomarkers of Response in Novel Molecular Therapeutics. Title: “Identification of potential biomarkers of response to OMO-103, a first-in-modality pan-MYC inhibitor, in patients with advanced solid tumors”. Selected Speaker.

2023 Cancer Biology module. Brunel University, London, United Kingdom. Meet the scientist: “A new generation of mini-proteins for cancer treatment”. Invited speaker.

2023 Seminar for the Transfer Technology Course of the Pasqual Maragall Foundation in Barcelona, Spain. Title: “The Omomyc experience: from bench to bedside”. Invited Speaker.

2022 Scientific Session of the Biochemistry and Molecular Genetics Service at the Hospital Clinic, Barcelona, Spain. Title: “Therapeutic mini-proteins against MYC for cancer treatment: from the bench to clinical trials”. Invited Speaker.

2022 15th International Symposium on Translational Research in Oncology (TransOncXV), Dublin, Ireland. Title: “Developing a clinically viable MYC inhibitor for cancer treatment”. Invited Speaker.

2022 44º Congress of the Spanish Society of Biochemistry and Molecular Biology (SEBBM), Malaga, Spain. Coordinator, Chair and Speaker of the session “Entrepreneurship and

Innovation". Title: "A clinically viable anti-MYC protein therapeutic for cancer treatment". Invited Speaker.

2022 ESMED (European Society of Medicine) General Assembly, Madrid, Spain. Title: "A clinically viable anti-MYC protein therapeutic for cancer treatment". Invited Speaker.

2022 II Scientific Meeting Day of the Department of Pathology and Experimental Therapy, Universitat de Barcelona (UB), Barcelona, Spain. Title: "Development of a viable MYC inhibitor for clinical use: the challenge of an "undruggable" target". Keynote speaker.

2022 Molecular Biomedicine Seminar Series at the Margarita Salas Center of Biological Research (CIB)-CSIC, Madrid, Spain. Title: "Development of a viable MYC inhibitor for clinical use: the challenge of an "undruggable" target". Invited speaker.

2022 VIII Edition Biomedical Cancer Research Conference, A Coruña, Galicia, Spain. Online Talk. Title: "The journey of a first-in-class MYC inhibitor from bench to clinical trial". Invited speaker.

2022 Collaborative Research Centre (CRC1321) Conference "Targeting and Modelling Pancreatic Cancer", Hohenkammer, Germany. Title: "A clinically viable MYC inhibitor for cancer treatment". Invited speaker.

2022 Seminar at Hospital Clinico de La Comunidad Valenciana (INCLIVA Foundation), Valencia, Spain. Title: "Development of mini-protein therapeutics against MYC for cancer treatment: from the laboratory to the clinical trials". Invited speaker.

2022 Irish Association for Cancer Research (IACR) Congress, Cork, Ireland. Online. Plenary session on "Novel Therapeutics". Title: "A first-in-class MYC inhibitor in clinical trial" Invited speaker.

2022 Seminario web Iberoamericano. Online. Title: "Estudios en oncoproteínas Myc en general y en biomarcadores". Invited speaker.

2022 Protein Degradation & Targeting Undruggable Congress. Boston, USA. Online. Title: "Anti-Myc mini-proteins for cancer treatment". Invited speaker.

2022 Cancer Biology module. Brunel University, London, United Kingdom. Meet the scientist: "Development of the anti-MYC drug Omomyc, from laboratory bench to the clinic". Invited speaker.

2021 Targeting the (un)usual suspects in cancer – 29th IGB (Institute of Genetics and Biophysics, Adriano Buzzati Traverso, Naples, Italy) Workshop. Virtual meeting. Title: "A new generation of mini-proteins against MYC for cancer treatment". Invited speaker.

2021 JPhD 2021: 6th PhD Scientific Meeting of the Univerisdad Autonoma de Barcelona (UAB). Title: "Challenges and opportunities for a MYC inhibitor in cancer treatment". Plenary Session. Invited speaker.

2021 V Translational Meeting Spanish Melanoma Group (GEM) 2021. Virtual Meeting. Closing Lecture. Title: "New strategies to overcome cancer: Myc inhibition as target therapy". Invited speaker.

2021 Women and Girls in STEM Forum, organized by Girls Go Circular, in collaboration with the European Commission, Directorate-General for Education, Youth, Sport and Culture (DG EAC). Virtual meeting. Closing Plenary Session Inspirational Talk. "The challenge of an "undruggable" target". Invited speaker.

2021 XIII Workshop SEQT: therapies with light and new advance therapies, organized by the Spanish Society of Therapeutic Chemistry (SEQT). Albacete, Spain. Title: "A first-in-class mini-protein against MYC as a novel cancer therapy". Invited speaker.

2021 II ASPIC-ASEICA International Meeting. Current Trends in Precision Medicine in Cancer. Title: "Challenges and opportunities for a MYC inhibitor in cancer treatment". Virtual event. Invited speaker.

2021 XIX Translational Research and Gastrointestinal Neoplasias Day organized by the Catalan Institute of Oncology (ICO). Badalona, Spain. Title: “MYC inhibition as therapeutic opportunity for the treatment of colorectal cancer”. Invited speaker.

2021 UCL Cancer Seminar Series. Title: “Development of a new generation of anti-Myc mini-proteins for cancer treatment”. Virtual event. Invited Speaker.

2021 Transcription Factor Drug Development 2021 Virtual Summit. Title: “Development of a new generation of anti-Myc mini-proteins for cancer treatment”. Virtual Event. Invited Speaker.

2021 Board of Trustees of Worldwide Cancer Research, UK. Title “Developing novel therapeutics against an “undruggable” target”. Virtual Event. Invited Speaker.

2021 5th VPH Summer School on Tackling Complexity in Health & Medicine. Title “A new generation of mini-proteins for cancer treatment”. Virtual Event. Keynote Speaker.

2021 Cancer Core Europe lecture. Education Task Force. Title: “Strategies and opportunities to target the undruggable target MYC”. Virtual Event. Invited Speaker.

2021 AACR 2021 Annual Meeting. Educational Session: Drugging Undruggable Targets. Title: “Challenges and opportunities of MYC targeting”. Invited Speaker.

2021 CERFA (Society of Spanish Scientists in the Federal Republic of Germany) Cancer Symposium. Title: “Attacking an “undruggable” target to combat cancer”. Invited Speaker.

2021 Webinar SEBBM Grupo Química Biológica, organized by IMIBICC. Title: “Attacking Myc with a new generation of cell-penetrating mini-proteins.” Invited speaker.

2021 Online Events for Cancer Patients organized by the Vall d’Hebron Institute of Oncology. Title: “From scientific discovery to clinical trial”. Invited Speaker.

2021 Undruggable Leaders Forum Virtual Event, “Rising Stars: Who’s breaking through?” Session. Title: “Getting to the clinic with a First-In-Class Direct Myc Inhibitor”. Invited Speaker.

2021 ANI-EIT Health Event. Talk about the success story of PEPTOMYC. Invited guest and Speaker.

2021 SEED & SOIL ECUSA. Round table. Talk about professional experience and investigation lines. Invited guest and speaker.

2021 MSCA Cancer Cluster Event. “Peptomyc: reimagining cancer treatment“. Invited online video poster presentation.

2021 Debate within the framework of the Barcelona 2041 program. Session: Barcelona de la Ciencia. Discussion about the challenges of the scientific sector in Barcelona. Invited speaker.

2021 Seminar series “Research Lines Update” of the Pathological Anatomy Department at the Vall d’Hebron Hospital, Barcelona, Spain. Title: “Developing anti-MYC mini-proteins to combat cancer”. Invited Speaker.

2020 SIP and Catalonia Life Science Industry Promotion Seminar (to promote China-Catalan Investment Opportunities in Biotech), Virtual Meeting. Invited Pitch.

2020 17th ASEICA International Congress. Title: “Drugging the “undruggable”: attacking MYC to combat cancer”. Invited Speaker.

2020 Opening Ceremony of the Biochemistry, Molecular Biology and Biomedicine Master and PhD Program 202-2021 of the Autonomous University of Barcelona (UAB). “Chasing MYC: a journey from basic research to the clinic”. Keynote Speaker.

2020 Round Table with the Magazine “Emprendedores”. Casa Seat, Barcelona, Spain. Invited guest and speaker.

2020 The Cellular Networks Cancer (CNC) Program – Spotlight on MYC Virtual Retreat [joint event CNC/CPRIT (Cancer Prevention & Research Institute in Texas)]. Title: “Omomyc-based mini-proteins as potential therapies for multiple tumor types”. Invited Speaker.

2020 ASEICA4You Program - Meet the Expert; Virtual. Title: “Chasing an undruggable target: from basic research to a start-up”. Invited Speaker.

2020 WIRED Health: Tech workshop run through; Virtual Conference. Webinar Panel: Healthcare innovation and startups in the digital age. Invited Panelist and Speaker.

2020 Mechanisms and Models of Cancer (Virtual) Meeting, CSHL. “Validation of Omomyc-based mini-proteins as potential therapies for multiple tumor types”. Invited speaker.

2020 Transcription Factors Drug Development Conference, Digital Event. “Attacking MYC with cell-penetrating mini-proteins”. Invited speaker.

2020 “Biología sintética”. Acció. Generalitat de Catalunya. Invited speaker.

2020 Stockholm Virtual MYC Meeting. “Omomyc-derived protein drugs: a step closer to MYC inhibition in the clinic”. Invited speaker.

2020 Píldora formativa. “Financiación y estratégias de licencia”. Red Innova Consulting. Invited speaker.

2020 Sixth Congress of Oviedo University Medicine Students. “The great challenge of cancer treatment: attacking “undruggable” targets. Opening keynote speaker.

2020 Facultad de Medicina Seminar Series, Hospital Clinic, Campus Clinic, Barcelona. “Defeating dogmas: drugging “undruggable” targets in cancer”. Invited speaker.

2020 Sixth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic. San Diego, California, USA. “A new generation of anti-Myc mini-proteins as potential therapy for NSCLC”. Invited Speaker.

2019 CNIO Lab Day 2019. Madrid, Spain “Myc and beyond. From basic research to a start-up”. Invited Speaker.

2019 NOV-FEBPS Anti-Cancer Symposium: Anti-cancer Drug Development against Undruggable Cancer Targets. Seoul, South Korea. “Novel Myc inhibitory strategies as powerful aids against cancer”. Invited Speaker.

2019 Turku Receptor Programme Annual Symposium. Aitiopaikka, Turun Virastotalo, Turku. “Defeating dogmas: drugging “undruggable” targets in cancer”. Invited Speaker.

2019 1st International HCSC – Symposium on Translational Cancer Research: From Basic science to clinical Benefit, University Complutense de Madrid, Spain. “Strategies to inhibit MYC in cancer”. Invited Speaker.

2019 Biotechnology and Biochemistry Institute, Universidad Autonoma de Barcelona, Spain. “Defeating dogmas: drugging undruggable targets in cancer”. Keynote speaker.

2019 Extraordinary Course by University of Zaragoza. 1st Molecular and Cellular Biology of Cancer School. Cancer in the XXI century: a call for researchers. Jaca, Spain. “The big challenge in cancer research: attacking the undruggable targets”. Invited speaker.

2019 Karolinska Institutet, Stockholm, Sweden. “Exploring undruggable targets: Inhibiting Myc to treat cancer”. Invited talk.

2019 CERCA (Catalan Research Centers Institution), Convent de Sant Agustí, Barcelona, Spain. “Tips for ERC Applications: learning from practice – The Proof of Concept”. Invited talk.

2019 IV Bellvitge Biomedical Research Institute (IDIBELL) PhD Day, Duran y Reynals Hospital, Barcelona, Spain. “The promise of drugging undruggable targets : a new generation of anti-Myc peptides for cancer treatment”. Keynote Speaker.

2018 Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. “Drugging the undruggable: treating cancer with anti-Myc peptides”. Invited talk.

2018 Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany. “Drugging the undruggable: anti-Myc polypeptides to treat cancer”. Invited talk.

2018 Frankfurt Cancer Conference, Goethe University, Frankfurt, Germany. “Inhibiting Myc with Omomyc-derived peptides”. Invited talk.

2018 Onco Emergence Forum Barcelona, Barcelona, Spain. “The promise of drugging the “undruggable”: targeting Myc to treat cancer”. Invited talk.

2018 Seminar at Brunel University, London, United Kingdom. “Drugging the undruggable: a new generation of anti-Myc cell penetrating peptides for cancer treatment”. Invited talk.

2018 AACR Annual Meeting. Chicago, USA. Session: Targeting Oncogenes, Tumor Suppressors, or Gene Products. "Omomyc-based cell-penetrating peptides: From proof of concept to a clinically viable anti-Myc therapy". Poster.

2018 AACR Annual Meeting. Chicago, USA. Session: Exploring Oncogenic Transcription Factors. "Myc inhibition by Omomyc impairs melanoma growth and progression through genome-wide gene expression reprogramming". Poster.

2018 Talk at the Innovation in Breast Cancer Symposium, Madrid, Spain. “Can we drug the "undruggable" cancer targets?”. Invited talk.

2018 Seminar at the GENYO, Parque tecnológico Ciencias de la Salud, Granada, Spain. “Drugging the undruggable: Preclinical validation of an Omomyc cell-penetrating peptide as a viable anti-Myc therapy”. Invited talk.

2017 Frontiers in Cancer Science 2017, Singapore. “Targeting the Undruggable: Inhibiting Myc with Omomyc-derived Peptides”. Invited talk.

2017 Seminar “Pushing Myc inhibition towards the clinic”, VIBes in Biosciences conference, Ghent, Belgium. Invited talk.

2017 Seminar “Targeting the "undruggable": Inhibiting Myc in cancer”, Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands. Invited talk.

2017 7th Claus per Bioempendre, Barcelona, Spain. First steps: from the idea to the first rounds of investment. Invited talk.

2017 HEALTHIO – Global Meeting of Health Innovation. Barcelona, Spain. Anti-Myc therapeutic peptides as a new cancer treatment. Invited talk.

2017 AACR Annual Meeting. Washington, USA. Session: Targeting p53, Apoptosis, and the Cell Cycle. "Preclinical validation of an Omomyc cell-penetrating peptide as a viable anti-Myc therapy". Poster.

2017 University of Murcia. Title: “Targeting the undruggable: inhibiting Myc with Omomyc-derived peptides”. Murcia, Spain. Invited speaker.

2016 European Commission organized Scientific Conference: Non-animal approaches – The way forward. Title: The EurOPDX Consortium: Objectives, Achievements & Future Directions in developing PDXs and derivatives". Brussels, Belgium. Poster.

2016 9th European Scientific Oncology Conference (ESOC). Title: "Targeting Myc by a new generation of cell penetrating peptides". Marbella, Spain 3–4 November, 2016. Invited speaker.

2016 B-Debate, Beyond Cancer Genomes. Barcelona Conference on Epigenetics and cancer. Title: "New first-in-class anti-Myc therapeutics". Barcelona, Spain 13– 14 October, 2016. Invited speaker.

2016 Entrepreneurs in Clinical Academia, ECA course. Session: How I became an academic biotech entrepreneur. Fontainbleau, France 3 – 7 October, 2016. Invited speaker.

2016 Vall d´Hebron Institute of Oncology (VHIO) Special Symposium:
Towards Predictive Cancer Models, Barcelona, 26 – 27 May, 2016. Organizer and speaker. "Drugging the "Undruggable": Inhibiting Myc to Combat Cancer".

2016 AACR Annual Meeting. New Orleans, USA. Session: Translational and Therapeutic Relevance of Perturbations of Gene Regulation in Malignancy. "Preclinical validation of Omomyc cell-penetrating peptides as a viable in vivo anti-Myc therapy". Poster.

2016 The European Meeting of Neuroscience for Doctoral Students, Grenoble, France. "Targeting the "undruggable" Myc in glioblastoma". Keynote speaker.

2016 XII Biennial Carbohydrate meeting / III Biennial Chemical Biology meeting. Madrid, Spain. "Treating cancer with anti-Myc cell penetrating peptides". Invited speaker.

2016 Instituto de Investigación Biomédica (IRB), Barcelona, Spain. Targeting the "undruggable": Inhibiting Myc in cancer. Invited speaker.

2015 European School of Molecular Medicine (SEMM), Milan, Italy. "Targeting the 'undruggable': inhibiting Myc in cancer". Invited speaker.

2015 8th Biennial Congress of the Spanish Society for Gene and Cell Therapy (SETGYC), San Sebastian, Spain. "Preclinical validation of a new generation of anti-Myc cell-penetrating peptides". Invited speaker.

2015 Wurzburg University, Wurzburg, Germany. "Targeting the 'undruggable': inhibiting Myc in cancer". Invited speaker.

2015 Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain. "How to target the 'undruggable': inhibiting Myc in cancer". Invited speaker.

2015 Centro de Investigación del Cáncer (CIC), Salamanca, Spain. "How to target the 'undruggable': inhibiting Myc in cancer". Invited speaker.

2015 CERCA Conference: Challenges to Accelerate Knowledge and Technology Transfer Processes, Barcelona, Spain. "How to target the 'undruggable': inhibiting Myc in cancer". Invited speaker.

2015 CancerBio summer school 2015, Helsinki, Finland. "How to target the 'undruggable': inhibiting Myc in cancer". Invited speaker.

2015 Conference: "Cracks de la Investigación para fabricar el futuro – 1": "A new efficient therapeutic therapy against cancer". Barcelona, Spain. Invited speaker.

2015 AACR Annual Meeting 2015. Philadelphia, USA. ERC session: "Funding opportunities in Europe for creative minds from anywhere in the world". 18-22 April 2015. Invited speaker.

2015 6th IMPPC Annual Conference 2015: Molecular targets for predictive and Personalized Medicine of Cancer. “Preclinical validation of Myc inhibition by a new generation of Omomyc-peptides”. 8-10 April 2015, Barcelona, Spain. Invited Speaker.

2015 II International Course in Cancer Biology: from Basic to Clinic. Cancer Summer School, University of Concepción, Chile. Classes: “Experimental models of cancer” and “Myc inhibition in mouse models”.

2015 AACR Meeting: MYC: From Biology to Therapy. San Diego, USA. “Pushing Myc inhibition towards the clinic by direct delivery of cell-penetrating peptides”. Poster.

2014 IMPPC (Institute of Personalized and Predictive Cancer Medicine), Badalona, Spain. “Myc inhibition in cancer therapy: getting closer to the clinic”. Invited Speaker.

2014 Ibrutinib Advisory Board Meeting, San Francisco, U.S.A. “Pre-Clinical Data in Solid Tumors and Discussion”.

2013 IDIBELL (Biomedical Research Institute of Bellevitge), Barcelona, Spain. “'Myc inhibition: a feasible strategy in cancer therapy”.

2013 14th Association for Spanish Cancer Research (ASEICA) International Conference, Madrid, Spain. “Myc inhibition as a therapeutic strategy in cancer”.

2013 96th Canadian Chemistry Conference, Quebec City, Quebec, Canada. “Myc: A Non-redundant Function in Cancer”.

2013 University College of Dublin (UCD), Dublin, Ireland. “Myc inhibition: a new viable approach to cancer therapy”.

2013 AACR Annual Meeting 2013, Washington, USA. “MYC inhibition is a potent therapy against glioma and induces mitotic crisis in cancer cells”.

2013 The Technische Universität München (TUM; University of Technology, Munich), Munich, Germany. “Inhibiting Myc and its inflammatory effectors as potential cancer therapies”.

2012 Hellen Diller Comprehensive Cancer Center, University California San Francisco, San Francisco, CA, USA. “Inhibiting Myc and its inflammatory effectors as potential cancer therapies”.

2012 Département de Pharmacologie Faculté de Médecine et de Sciences de la Santé Université de Sherbrooke, Sherbrooke, QC, Canada. "Myc: a non-redundant function in cancer"

2012 Department of Experimental Oncology, Campus IFOM-IEO, Milano, Italy. “Pre-clinical validation of Myc as a target in cancer therapy”.

2012 FPRC - Fondazione Piemontese per la Ricerca sul Cancro ONLUS, Torino, Italy. “Pre-clinical validation of Myc as a target in cancer therapy”.

2011 Department of Histology and Medical Embryology, University La Sapienza, Roma. “Inibizione dell’oncoproteina Myc in tumori e microambiente come potenziale terapia anti-cancro.”

2011 iSymposia: Mouse Models of Cancer. “Inhibiting Myc and its inflammatory effectors as a therapeutic strategy against cancer”. Virtual conference.

2011 Barcelona Biomed Conference “Signal Rewiring and Addiction in Cancer”, Institute for Research in Biomedicine (IRB Barcelona). Title: “Myc: a non redundant function in cancer”.

2011 Hospital San Raffaele PhD meeting, Milan, Italy. Title: "Inhibition of Myc and Myc-related inflammatory response as effective therapies in various mouse models of cancer".

2010 MRC, Cancer Cell Unit, Cambridge, UK. Title: “Inhibiting Myc and the Myc-dependent inflammatory response as cancer therapies”.

2010 Cold Spring Harbor Laboratory, “Mechanisms and models of cancer” Meeting. Title: “Myc inhibition has a dramatic therapeutic impact in diverse mouse models of cancer”.

2010 Institute of Oncology Vall d’Hebron, Barcelona, Spain. Title: “Inhibiting Myc and the Myc-dependent inflammatory response as cancer therapies”.

2010 Lowy Symposium: Discovering Cancer Therapeutics. Sidney, Australia. Title: “Deconstructing oncogenesis and tumour suppression to find the best cancer targets” .

2010 AACR 101th Annual Meeting, Washington DC, USA. Title: “Mast cell inhibition by Btk inhibitor PCI-32765 as a potential cancer therapy”

2010 Ecole Polytechnique Fédérale de Lausanne (EPFL) and Institut suisse de recherche expérimentale sur le cancer (ISREC), Lausanne, Switzerland. Title: “Inhibiting Myc and the Myc-dependent inflammatory response as Cancer therapies”

2010 University of Cambridge, Department of Biochemistry, Cambridge, UK. Title: “Inhibiting Myc and the Myc-dependent inflammatory response as Cancer therapies”

2009 Barts and the London School of Medicine and Dentistry, London, UK. Title: “Inhibiting Myc and the Myc-dependent inflammatory response as Cancer therapies”

2009 Salk Institute, San Diego, CA, USA. “Mechanisms and Models of Cancer”. Title: Myc Inhibition as a Cancer Therapy”

2009 Istituto Biologia e Patologia Molecolari, CNR, Rome, Italy. Title: “New data regarding Myc inhibition in pancreatic cancer”.

2009 Universita’ La Sapienza, Rome, Italy. Title: “Myc inhibition in cancer: bright new hope or bad idea?”

2009 Institute of Oncology Vall d’Hebron, Barcelona, Spain. Title: “Myc inhibition in cancer: bright new hope or bad idea?”

2008 Cold Spring Harbor Laboratories Meeting Mouse Models of Cancer: Title: “Modeling Myc Therapeutic Potential In Vivo”

2008 AACR Annual Meeting in San Diego, USA; invited speaker at the Special Symposium “Future Leaders, New directions”. This special symposium was created in 2007 at the request of Dr. Geoffrey M.Wahl, then President of the AACR, to showcase the best and brightest among trainee researchers in the cancer fields

2007 Keystone Symposia: Inflammation and Cancer. Title: “Mast cells are required for expansion of Myc-dependent tumors”

2003 EMBL Mouse Biology Unit based at the Monterotondo Outstation near Rome, Italy. “Omomyc expression in skin prevents Myc-induced papillomatosis”,

2001 Annual oncogene meeting, Salk Institute, San Diego, CA.

2000 Workshop on The Myc network: Regulation of Cell Proliferation, Differentiation and Death, Instituto Juan March de Estudios y Investigationes. “Omomyc: a new tool to better understand Myc function”

2000 International meeting on oncogenes. Positano, Amalfitan Coast, Salerno, Italy. “Omomyc: a new tool to better understand Myc function”.

Certifications

2014 Italian Associate Professorship Accreditation

2006 Lab Management and leadership UCSF, CA, USA

1998 Italian National Certification of Biology

Courses attended

2023 “Training Course in Leadership and Management Skills” by Hfp consulting, sponsored by ICREA, Barcelona, Spain.

2023 “Psychosocial Risks Prevention” Course by VHIO, Barcelona, Spain.

2021 “Conflict management and resolution” Course by VHIO, Virtual.

2020 “The Pharma Business Development” Course by CELforPharma, Virtual.

2018 “Advanced Business Development” by EBD Academy, Copenhagen, Denmark.

2018 “The pharmaceutical-out licensing course” Course by CELforPharma, Copenhagen, Denmark.

2018 “Moonshot Thinking for Entrepreneurs” – Singularity University, Palo Alto, CA, USA.

2018 “Ignite” Course 2018 – Entrepreneurship Centre, Judge Business School, Cambridge, United Kingdom.

2016 “Claus Per Biompendre” – Introduction to Bioentrepreneurship. Barcelona, Spain.

2016 “Time Management” Course by VHIO, Barcelona, Spain.

2008 “Setting Goals for your career direction and Professional Growth” Course, UCSF,

San Francisco, CA

2008 “Lab leadership and Management” UCSF, San Francisco, CA

2005 Becoming an Effective Science Teacher (BEST) Course, UCSF, San Francisco, CA

1998 “Molecular Modelling for beginners” EMBL, Heidelberg, Germany

1995 “Developmental and Functional Aspects of Human Brain” University of Trieste and Udine, S.I.B.B.M. and CE.PRO.BI.MOL., Cividale del Friuli (UD), Italy

Mentoring

Supervision of PhD students, VHIO/Peptomyc, Spain:

2016-2020 Sandra Martínez Martin (Biomarkers Project Manager at Peptomyc S.L.)

2012-2018 Toni Jauset González (now Medical Science Liaison at Alkermes)

2013-2017 Daniel Massó-Vallés (now Medical Science Liaison at Alkermes)

2020- Hugo Thabussot

2020- Iñigo Gonzalez Larreategui

2020- Fabio Giuntini

Supervision of Fullbright fellow, VHIO, Spain:

2018 Jessica Chambers

Supervision of master students, VHIO, Spain:

2017 Erika Lutzu (visiting student from Italy)

2016 Ana Garcia Cerdeño (score of 9.98/10 for master thesis)

2015 Sandra Martinez (score of 9.6/10 for master thesis; now PhD student in the lab)

2022-2023 Daniel Capitan Leo (score of 9.9/10 for master thesis; now PhD student in the lab)

2023-2024 Manuel Lillo Valero

2024 Xavier Thillen Raluy

Supervision of Postdocs, VHIO/Peptomyc, Spain:

2020-2021 Sandra Martinez Martín (now Biomarkers Project Manager at Peptomyc S.L.)

2019-2022 Jastrinjan Kaur

2018-2020 Toni Jauset González (now Medical Science Liaison at Alkermes)

2017-2018 Daniel Massó-Vallés (now Medical Science Liaison at Alkermes)

2016-2017 Silvia Casacuberta (now Immunology Project Manager at Peptomyc S.L.)

2016- Mariano Zacarías-Fluck (now Senior Scientist in the lab)

2013-2016 Marie-Eve Beaulieu (now CSO of Peptomyc S.L.)

Supervision of summer students, VHIO, Spain:

2013 Justyna Wierzbińska

2012 Lorena Moreno Calle

Supervision of postdocs, UCSF, USA:

2009-2010 Daniela Annibali, visiting postdoc from Italy

Supervision of BMS students, UCSF, USA:

2007 Neil Sheehy

2006 Rebecca Lock

2005 Daniel Garcia

Supervision of undergraduate students, University La Sapienza, Rome, Italy:

2003 Nicoletta Carucci

2002-2003 Daniela Annibali

1998-2000 Laura Panacchia

1998-2000 Roberta Ciarapica

1997 Alessandra Sacco

Teaching

2023	Class “Preclinical studies before clinical trials can start” in the II Edition of HEMPOWER (Empower Research Skills on Hematology) course sponsored by VHIO and Astrazeneca, Barcelona, Spain.
2023	Class for Master Students in Laboratory Animal Science and Welfare, Veterinary Faculty of Universitat Autonoma de Barcelona. “Experimental models in oncology”.
2022	Class “Preclinical studies before clinical trials can start” in the HEMPOWER (Empower Research Skills on Hematology) course sponsored by VHIO and Astrazeneca, Barcelona, Spain.
2022	“Meetings with scientists”: Talk among 3 women: a scientist, an entrepreneur and a Venture Capital representative, where students can interact and ask questions. Comunicación y Cultura Científica of the National Museum of Natural Sciences, in collaboration with: Woman and science Group of the Spanish Society of Biochemistry and Molecular Biology (SEBBM), AseBio and Spanish Association of Research against Cancer (ASEICA). Madrid, Spain.
2022	Spanish Association of Research against Cancer (ASEICA) initiative: “CONÓCELAS”: Inspirational talk for students from Escola Grèvol, Barcelona, Spain.
2021	Spanish Association of Research against Cancer (ASEICA) initiative: “CONÓCELAS”: Inspirational talk for sixth grade students (11 years old) to encourage kids, especially girls, to undertake a career in science. Institut Vapor del Fil, Barcelona, Spain.
2021-	EIT Health Mentor
2020-	ASEICA (Spanish Association of Cancer Research) Mentor. ASEICA4You Program.
2013-	Annual Class for Master Students in Translational Medicine (Experimental Models of Translational Research Course) “Experimental models in cancer”. University of Barcelona (UB).
2020	MECUSA (Spanish Women Scientists in USA) Small Molecules and Biologics Workshop. Virtual Meeting. “Scientists as CEOs” class.
2020	5th Barcelona VPH Summer School Virtual Meeting. “A new generation of mini-proteins for cancer treatment”. Keynote lecturer
2020	Class “MYC’s role in cancer” for the Senology Master of the University of Barcelona Campus Clinic, Module: “Research, Biostatistics and molecular biology in breast cancer”.
2018	Vocational/Professional Guidance Day at the Vall d’Hebron Hospital. Discussion Panel: “Professional opportunities in the career of a researcher”. Invited panelist.
2016	Class for Master Students in Laboratory Animal Science and Welfare, Veterinary Faculty of Universitat Autonoma de Barcelona. “Experimental models in oncology”.
2015	II International Course in Cancer Biology: from Basic to Clinic. Cancer Summer School, University of Concepción, Chile. Classes: “Experimental models of cancer” and “Myc inhibition in mouse models”.
2015	8th Annual CancerBio Summer School, Biomedicum Helsinki, Finland. Class: “How to target the “undruggable”: Inhibiting Myc in cancer”.
2010	Small group leader in Methods, Mechanisms and Malignancies, Small Group Teaching for 2nd year Medical students at UCSF.

2009	Small group leader in Methods, Mechanisms and Malignancies, Small Group Teaching for 2nd year Medical students at UCSF.
2008	Small group leader in Methods, Mechanisms and Malignancies, Small Group Teaching for 2nd year Medical students at UCSF.
2007	Postdoc Teaching Fellowship in Cancer: Bench to Bedside (CBB): Molecular Biology Small Group Teaching to 2nd year Medical students at UCSF

Teaching Awards and Nominations

2008	Essential Core Teaching Award for Excellence In Small Group Instruction Nomination
2007	Essential Core Teaching Award for Excellence In Small Group Instruction Nomination
2006	Essential Core Teaching Award for Excellence In Small Group Instruction Nomination

Other Activities

2024 – 2025	Member of the AACR-AstraZeneca Career Development Award for Physician Scientists, in Honor of José Baselga Scientific Review Committee.
2023 -	Leader of the International Branding Group and core member of the Life Science Chapter of Barcelona Global
2023-	Jury Member of the CaixaImpulse Innovation Selection Committee 2023 - Therapeutics
2023	Member of Expert Working Groups of UNCAN.eu (European Initiative to UNderstand CANcer)
2023 -	Evaluation panel member for the ERC Consolidator Grant.
December 2022-	member of the AACR Lung Cancer Research Grants Scientific Review Committee.
2022	Jury Member of the CaixaResearch Validate Selection Panel 2022 - Therapeutics.
2022 -	Evaluation panel member for the ERC Starting Grant.
July 2021-	Coordinator of the Innovation and Entrepreneurship group of the SEBBM (Spanish Society of Biochemistry and Molecular Biology).
February 2021-	Member of the Scientific Advisory Board of Radyus Research, USA.
January 2021-	External Scientific Committee Member at Research Foundation of HOSPITAL CLINICO DE LA COMUNIDAD VALENCIANA (FUNDACION INCLIVA), accredited Health Research Institute by the Carlos III Health Institute in Valencia, Spain.
November 2020-	Member of the Internal Scientific Committee of the Vall d'Hebron Health Research Institute (ISSA IR HUVH).
2020	Jury Member for the Catapult Biotech Semifinals organized by EIT (European Institute of Innovation and Technology) Health.

2020 Jury member in the mock interviews for ERC-CoG2020 organized by the European Office FECYT (Spanish Foundation for Science and Technology).

2020 Coordinator of the evaluations of FIS projects (Acción Estratégica en Salud), Spanish Ministry of Science and Innovation.

2019- Jury member for the Bioemprendedor XXI award, by Biocat, "la Caixa" y Barcelona Activa

2019- Scientific Co-chair at VHIO -"la Caixa" Foundation SCIENTIFIC SEMINARS SERIES

2019 Model for NIKE. Advertising campaign Barcelona FC, Spain.

2019- Member of the Scientific Committee of the FERO Foundation, Spain.

2018- Member of the Scientific Committee of VHIO, Spain.

2013- Member of the evaluation panel of the FERO Foundation Fellowship, Spain.

2018-2019 Member of the Scientific Review Committee for the "Anna Tramontano" research projects of La Sapienza Università di Roma, Italy.

2018 Member of the Scientific Advisory Board Meeting of Breast Cancer Now, UK's largest breast cancer research charity, UK.

2017-2018 Member of the Scientific Review Committee for the "Anna Tramontano" research projects of La Sapienza Università di Roma, Italia.

2018 Member of the Institute for Research in Biomedicine (IRB) Barcelona Philanthropy Fund External Scientific Committee, Spain.

2018 Member of the evaluation panel for the Bellevitge Biomedical Research Institute (IDIBELL) Research Groups, Spain.

2017-2018 Member of the AACR Clinical and Translational Cancer Research Fellowships Scientific Review Committee, USA.

2016-2017 Member of the AACR Clinical and Translational Cancer Research Fellowship Scientific Review Committee, USA.

2016-2017 Member of the AACR Judah Folkman Career Development Award for Angiogenesis Research, USA.

2016-2017 Member of the AACR Clinical and Translational Cancer Research Grants Scientific Review Committee, USA.

2014 Member of the Fundraising event for the Worldwide Cancer Research organism (WCR): trekking to the summit of Mt. Toubkal in Morocco (May 2014), which resulted in a charity of 40.000£ http://www.worldwidecancerresearch.org/fundraising/event/morocco-trek-cancer for cancer research.

Other Creative Activities including Teaching Aids

- Author of "An elephant under the Christmas tree", article of the British Council Magazine in Rome, in 1999
- Author of the short questions and multiple-choice questions for the midterm exams of second year Medical Students in Cancer: Bench to Bedside (CBB), Fall 2007
- Author of Teaching Material for Small Group "Advances in Treatment of Non-Small Cell Lung Cancer (NSCLC): Journal Club" in the Methods, Mechanisms and Malignancies, Fall 2008 for 2nd year medical students at UCSF.

- Author of Handbook of Translational Medicine, Chapter: “Experimental Models”.